Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by Alex1967on Aug 09, 2020 9:28am
190 Views
Post# 31384186

90% of recovered Covid-19 patients in Wuhan have damaged lun

90% of recovered Covid-19 patients in Wuhan have damaged lun
A team of doctors in China has claimed that lungs of 90 per cent of Covid-19 patients who recovered in Wuhan, the city where the outbreak of the disease was first reported, are still damaged.
The team is led by Peng Zhiyong, the director of Zhongnan Hospital of Wuhan University. It has been conducting follow-up visits with ‘100 recovered patients’ since April.
The findings of the research have been startling. Peng’s team said that the recovered patients could only walk for 400 metres in six minutes, unlike their healthy peers who could cover a distance of 500 metres in the same time. This is based on the walking test with the patients.
<< Previous
Bullboard Posts
Next >>